Malignant Biliary StricturesNCT01501474
Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures
An observational study of Malignant Biliary Strictures, run by King Chulalongkorn Memorial Hospital at 1 site in Thailand.
Trial summary
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures Objectives 1. To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis 2. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Malignant Biliary Strictures
- How many people
- 5 participants
- Where
- 1 siteThailand
- Study dates
- Jan 2012to Jul 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients
Who may be able to join
- Age > 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form
Who cannot join
- Cannot follow up for 1 year
- Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants
- Pregnancy
- History of fluorescein allergy
Trial locations and contacts
1 site in 1 country.
About this study
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
- To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
- To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Read the detailed description
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
- To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
- To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Inclusion Criteria
- Age > 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form Exclusion Criteria
1.Cannot follow up for 1 year 2.Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants 3.Pregnancy 4.History of fluorescein allergy
Timeline: From January 2012 to December 2013
Sample size Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients
Method
- All patients had informed the consent.
- Take the history, physical examination and then fill in the record form 3.5 ml of blood sampling for CA19-9 and 20 ml for further test by keeping in -20c temperature for 5 years
4.Set confocal endomicroscopy at the same session of ERCP 5.After successfully cannulation;
- 10% Fluorescein sodium 2.5 ml was injected intravenously.
- Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder. 6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;
- Thick branching bands (>20 microns)
- Dark clumps or glands (usually measuring > 60 microns)
- Bright and tortuous vessels Follow up
- The patients who are diagnosed malignant biliary obstruction will be treated as standard management
- The patients who are not diagnosed malignant biliary obstruction will be followed up every 3 months for 1 year
- The gold standard is pathology or clinical of malignancy including evidence of metastasis.
Statistical analysis Sensitivity, specificity, negative predictive value(NPV), positive predictive value(PPV) and accuracy by McNemar's test
Ethical considerations There is not a clearly evidence about the significant serious side effect of fluorescein injection. If the patients have side effects during the research, the procedure will be terminated and the patients will be in the responsibility of all investigators.
Expected benefit and application
- Increase rate of malignant biliary stricture diagnosis by using CholangioFlex and/or FISH test
- Decrease the mortality rate of malignant biliary stricture
- Conditions
- Malignant Biliary Strictures
- Keywords
- Confocal, malignant biliary stricture, Sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis, sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
- Medical subject headings
- Hypersensitivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| CholangioFlex and Fluorescent in situ Hybridization(FISH) | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Increasing the detection rate of malignant biliary stricture diagnosis by using CholangioFlex (Cofocal) and/or FISH test
If investigator can detect malignant biliary stricture more than present, the care giver can treat these patients properly. Consequently, the mortality rate of malignant biliary stricture will be decrease.
Measured: up to 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Dec 2011 (estimated)
- Study startJan 2012
- Primary completionJul 2014
- Study completionJul 2014
Why it stopped: No suitable case available and many techinical error
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant Biliary StricturesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- King Chulalongkorn Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rapat Pittayanon, MD, King Chulalongkorn Memorial Hospital
- Investigators
- Rapat Pittayanon, MD, Principal investigator, Chulalongkorn HospitalRungsun Rerknimitr, Professor, Study director, Chulalongkorn Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01501474
- Sponsor's protocol ID
- RP004
- Status last verified
- Feb 2019
- First submitted
- 27 Dec 2011
- Last updated
- 27 Feb 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Utility of CholangioFlex and Fluorescent in Situ Hybridization in the Diagnosis of Malignant Biliary Strictures
- ClinicalTrials.gov ID
- NCT01501474
- Acronym / sponsor ID
- RP004
- Conditions
- Malignant Biliary Strictures
- Keywords
- Confocal, malignant biliary stricture, Sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis, sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: No suitable case available and many techinical error
- Enrolment
- 5 participants (actual)
- Lead sponsor
- King Chulalongkorn Memorial HospitalUniversity, hospital or other
- Study start
- Jan 2012 (actual)
- Primary completion
- Jul 2014 (actual)
- Study completion
- Jul 2014 (actual)
- First posted
- 29 Dec 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
- To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
- To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Detailed description
Utility of CholangioFlex and Fluorescent in situ Hybridization in the Diagnosis of Malignant Biliary Strictures
Objectives
- To assess the sensitivity, specificity and accuracy of CholangioFlex in malignant biliary stricture diagnosis
- To assess the sensitivity, specificity and accuracy of Fluorescent in situ Hybridization(FISH) in malignant biliary stricture diagnosis
Study design One academic center, prospective, diagnostic study
Research Methodology Target population: Patients who are diagnosed malignant biliary stricture. Sample population: Patients who are diagnosed malignant biliary stricture in Chulalongkorn Hospital
Inclusion Criteria
- Age > 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form Exclusion Criteria
1.Cannot follow up for 1 year 2.Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants 3.Pregnancy 4.History of fluorescein allergy
Timeline: From January 2012 to December 2013
Sample size Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients
Method
- All patients had informed the consent.
- Take the history, physical examination and then fill in the record form 3.5 ml of blood sampling for CA19-9 and 20 ml for further test by keeping in -20c temperature for 5 years
4.Set confocal endomicroscopy at the same session of ERCP 5.After successfully cannulation;
- 10% Fluorescein sodium 2.5 ml was injected intravenously.
- Confocal endomicroscopy (CholangioFlex) was performed at the suspected area. The video will record the images with Cellvizio program recorder. 6.Brush cytology was performed 7.Record the duration and complication of the procedure 8.Send the tissues to one clinically-blinded GI pathologist for pathological diagnosis and FISH test 9.Compare the pathology and FISH report and endoscopic finding 10.Report the result According to Miami-criteria 2009, the Criteria for malignant biliary stricture from CholangioFlex are one of the followings;
- Thick branching bands (>20 microns)
- Dark clumps or glands (usually measuring > 60 microns)
- Bright and tortuous vessels Follow up
- The patients who are diagnosed malignant biliary obstruction will be treated as standard management
- The patients who are not diagnosed malignant biliary obstruction will be followed up every 3 months for 1 year
- The gold standard is pathology or clinical of malignancy including evidence of metastasis.
Statistical analysis Sensitivity, specificity, negative predictive value(NPV), positive predictive value(PPV) and accuracy by McNemar's test
Ethical considerations There is not a clearly evidence about the significant serious side effect of fluorescein injection. If the patients have side effects during the research, the procedure will be terminated and the patients will be in the responsibility of all investigators.
Expected benefit and application
- Increase rate of malignant biliary stricture diagnosis by using CholangioFlex and/or FISH test
- Decrease the mortality rate of malignant biliary stricture
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| CholangioFlex and Fluorescent in situ Hybridization(FISH) | – | – |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Due to no study in Thai population before, investigator will perform pilot study in 50 malignant biliary stricture patients
Key inclusion criteria (3 listed)
- Age > 20 year-old
- All patients who are diagnosed malignant biliary stricture by 3 months and undergo ERCP in Chulalongkorn Hospital.
- All patients have to sign the consent form
Key exclusion criteria (4 listed)
- Cannot follow up for 1 year
- Bleeding tendency including decompensated cirrhosis, chronic kidney disease and long-tem antiplatelets or anticoagulants
- Pregnancy
- History of fluorescein allergy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Increasing the detection rate of malignant biliary stricture diagnosis by using CholangioFlex (Cofocal) and/or FISH test
Time frame: up to 1 year
If investigator can detect malignant biliary stricture more than present, the care giver can treat these patients properly. Consequently, the mortality rate of malignant biliary stricture will be decrease.
Results and safety
The study was stopped early (reason given: No suitable case available and many techinical error). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2019.
- Related InfoLink provided by the sponsor.
Related trials for Malignant Biliary Strictures
Recruiting
Endoscopic Ultrasound Guided Hepaticogastrostomy With or Without Antegrade Stenting for Palliation of Malignant Distal Biliary Obstruction: Randomized Controlled Trial
Malignant Biliary Obstruction, Malignant Biliary Stricture
Not yet recruiting
The HANAROSTENT® Multi-Hole™ Biliary Stent is Indicated for Use in the Palliative Treatment of Biliary Strictures Produced by Malignant Neoplasms and the Study is to Demonstrate Clinical Safety and Performance of the Multi-Hole™ Stent for the Palliative Treatment of Malignant Biliary Obstruction.
Biliary Strictures Caused by Malignant Neoplasms
Active, not recruiting
Single-operator Digital Cholangioscopy for the Diagnosis of Malignant and Benign Biliary Strictures
Biliary Stricture
RecruitingPhase 2
Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis
Acute Cholangitis, Biliary Tract Infection
Active, not recruitingObservational study
Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)
Pancreatic Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rapat Pittayanon, MD principal investigator
Chulalongkorn Hospital
Rungsun Rerknimitr, Professor study director
Chulalongkorn Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Malignant Biliary Strictures, run by King Chulalongkorn Memorial Hospital at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 27 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: No suitable case available and many techinical error). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Increasing the detection rate of malignant biliary stricture diagnosis by using CholangioFlex (Cofocal) and/or FISH test (time frame: up to 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2019.